Delivery Order HHSN261201500038I-HHSN26100003
Award Date
9/24/15
Potential Completion Date
9/23/18
Potential Value
$598K
Federal Agency
National Cancer Institute
Awardee
University Of Oklahoma
Ultimate Awardee
University Of Oklahoma
NAICS Category
541711 - Research and Development in Biotechnology
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Cost No Fee
Place of Performance
Oklahoma City, OK 73104, USA
Solicitation Procedures
Multiple Award, Fair Opportunity
Number Of Offers Received
2
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a federal contract award for $686,894.80 by the National Cancer Institute (NCI) under the Preclinical Agent Development Assays 2012-2016 program. The award was made to the University of Oklahoma (OU) to test the efficacy of aspirin and omeprazole for colorectal cancer chemoprevention. This was a delivery order contract with a cost-no-fee pricing type, and there was no set-aside designation. OU is a public research university that provides a range of medical research, healthcare, and...
This is a federal delivery order contract awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU) for "OTHER FUNCTIONS - EFFICACY OF ASPIRIN AND NAPROXEN (SHORT-TERM-FREQUENT DOSING) IN COLORECTAL CANCER MODELS". The $770,757.36 contract is a cost-no-fee award that is part of the Preclinical Agent Development Assays 2012-2016 indefinite delivery/indefinite quantity (IDIQ) contract...
This federal contract award was issued by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU). The $633,898 firm fixed price delivery order is part of NCI's "Preclinical Agent Development Assays 2012-2016" indefinite delivery contract and supports research on the use of the drug naproxen for the prevention of colorectal cancer. The contract does not have a small business set-aside...
This is a firm fixed price Delivery Order awarded by the National Cancer Institute (NCI) to the University of Oklahoma (OU) for the "Prevention of Colorectal Cancer by ONC201" project. The contract, which is part of the NCI's "PREVENT Cancer Program", has a period of performance from September 2016 to September 2018 and a ceiling value of $221,345. The work is focused on preclinical cancer prevention research, specifically evaluating the efficacy of the drug ONC201 for...
This is a $521,214.97 Firm Fixed Price delivery order awarded by the National Institutes of Health (NIH) National Cancer Institute to the University of Oklahoma Health Sciences Center to conduct research on the chemoprevention of colorectal cancer with olmesartan medoxomil. The order is part of the NIH's PREVENT Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers for cancer prevention. The delivery order does not have a set-aside designation. University...
The University of Oklahoma (OU) has been awarded a $1,140,397 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program (PREVENT) master indefinite delivery/indefinite quantity (IDIQ) contract by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH). The delivery order is for a base title of the PREVENT Program involving preclinical efficacy and intermediate endpoint biomarkers. Specifically, the task order title is for...
The federal contract award, with ID 75N91019D00020|75N91020F00003, was granted by the National Cancer Institute to the University of Oklahoma Health Sciences Center Division, a public research university in Oklahoma City, Oklahoma. The contract is for the "PREVENT CANCER PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND ENDPOINT BIOMARKERS" with a task order titled "URINARY BLADDER CANCER PREVENTION WITH TWO CLINICALLY-READY AGENTS (EVEROLIMUS AND NAPROXEN) WHEN...
This is a federal contract award from the National Cancer Institute (NCI), a civilian agency within the Department of Health and Human Services, to the University of Oklahoma Health Sciences Center Division. The contract is part of the NCI's "PREVENT Cancer Program (PREVENT)" and covers a "CONTRACT ORIENTATION AND KICK-OFF MEETING" with a period of performance from September 22, 2015 to December 31, 2015. The contract has a ceiling value of $4,217.44 and is a Delivery Order...
This is a firm fixed-price delivery order awarded by the National Cancer Institute (NCI), a civilian agency within the U.S. Department of Health and Human Services, to the University of Oklahoma (OU) for "TARGETING CCK2R FOR PANCREATIC CANCER PREVENTION". The $474,197.46 contract is part of the NCI's Preclinical Agent Development Assays 2012-2016 program, which focuses on preclinical in vitro and in vivo agent development assays. The award does not have a set-aside designation. As...
This is a firm fixed-price delivery order contract awarded by the National Cancer Institute, part of the U.S. Department of Health and Human Services, to the University of Oklahoma Univ of Oklahoma Health Sciences Center Division. The $628,343 contract is for research and development related to the Preclinical Prevention Cancer Program, which focuses on preclinical efficacy and intermediate endpoint biomarkers. This work is not set aside for small businesses. The University of Oklahoma, acting...